Primary Prevention Aspirin Eligibility Under a Contemporary Risk Framework - Summary - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Eligibility for Aspirin in Primary Prevention Using a Contemporary Cardiovascular Risk Framework

  • By

  • Sridhar Mangalesh

  • Sharanya Kaushik

  • Raiza Rossi

  • Armin Nouri

  • Shefa Arya Nezhad

  • Abdulla A. Damluji

  • Michael G. Nanna

  • November 19, 2026

Share

Objective:

To compare estimated primary-prevention aspirin eligibility using PREVENT-ASCVD risk thresholds with eligibility based on the USPSTF’s PCE threshold of 10% or greater among US adults aged 40 to 59 years without prior ASCVD or selected major bleeding-risk characteristics.

Approach:
  • Design and data: Cross-sectional analysis of publicly available NHANES data from 2013–2020, using survey weights to produce nationally representative estimates.
  • Participants: Included 4,289 adults aged 40–59 years; excluded those with prior ASCVD or specified characteristics associated with major bleeding risk.
  • Risk comparison: Compared PCE eligibility at 10% or greater with PREVENT-ASCVD eligibility at thresholds of 5%, 7.5%, and 10% or greater.
Key Findings:
  • Overall estimated eligibility was 8.5% using PCE at 10% or greater, compared with 10.4%, 3.4%, and 1.1% using PREVENT thresholds of 5%, 7.5%, and 10%, respectively.
  • Among aspirin nonusers, PCE classified 7.4% as eligible; PREVENT at 5% classified 8.7%, the closest estimate to PCE.
  • Among PCE-eligible aspirin nonusers, 17.2% would no longer qualify at PREVENT 5%, 66.5% at 7.5%, and 89.9% at 10%.
  • Each PREVENT threshold also identified aspirin nonusers who were not eligible under the PCE criterion.
Interpretation:

In this analysis, PREVENT thresholds from 5% to 10% substantially changed estimated aspirin eligibility relative to the PCE threshold. A PREVENT threshold of 5% produced population-level eligibility estimates most similar to PCE at 10%; the study did not establish a PREVENT-specific threshold for aspirin discussions.

Limitations:
  • ASCVD history and aspirin use were self-reported, so some participants may have been misclassified.
  • Bleeding risk was assessed using pragmatic survey-based surrogates rather than a validated questionnaire item.
  • Excluding participants with bleeding-risk characteristics, some of which also increase cardiovascular risk, limits generalizability to people with both risks.
  • The analysis was cross-sectional and estimated eligibility; it did not evaluate aspirin treatment outcomes.
Conclusion:

The authors state that PREVENT-specific microsimulation studies evaluating thresholds between 5% and 10% are needed before recommendations can be formally revised for contemporary risk assessment.

Original Source(s)

Related Content